Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of GSK2402968 in ambulant Duchenne muscular dystrophy
NL-OMON36720Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing GSK2402968 with Placebo (2 arms). Primary endpoint: 6-minute walking distance. Started Jun 2011; status: active, not recruiting.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON36720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36720.